This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update

Table 24: Key Events Impacting Sales for Rheumatoid Arthritis in India, 2012 62

Table 25: Rheumatoid Arthritis Market - Drivers and Barriers in India, 2012 63

Table 26: Key Launch Dates 75

Table 27: Key Patent Expiries 75

Table 28: Physicians Surveyed, By Country 81

List of Figures

Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 10

Figure 2: Rheumatoid Arthritis Biologic Drug Targets 12

Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System 17

Figure 4: Severity of Rheumatoid Arthritis 17

Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations* 20

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 59

Figure 7: Sales for Rheumatoid Arthritis in India by Drug Class 61

To order this report: Pathology Industry: PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update


Nicolas BombourgReportlinkerEmail: nicolasbombourg@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626



SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs